ArticleMetabolic brain disease2026
Enhanced combined effect of thymoquinone and transcranial photobiomodulation on cerebral ischemia-induced injuries in animal model.
Article in Metabolic brain disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Various therapeutic approaches to reduce ischemic brain injuries have been somewhat ineffective. Thymoquinone (TQ), a bioactive compound in Nigella sativa, exhibits anti-inflammatory and antioxidant properties. Transcranial photobiomodulation (tPBM), also known as low-level laser therapy (LLLT), has neuroprotective effects by modulating inflammatory and apoptotic pathways. This study investigated whether the administration of TQ as a candidate for combination therapy with tPBM could reduce ischemic brain injuries. Eighty-five Wistar male rats were randomly assigned to five groups: sham, MCAO, TQ, tPBM, and TQ + tPBM. The MCAO group was subjected to middle cerebral artery occlusion (MCAO) surgery. The sham group underwent surgery without filament insertion. The TQ group received 15 mg/kg of intraperitoneal TQ immediately after filament removal. The tPBM group was treated using a Photino brain laser probe (810 nm, 8 mW, and 30.6 J/cm²), which was applied to the cerebral surface of the rats in three sessions, each lasting 2 min. At 24 h After reperfusion, neurological deficit scores (NDS), infarct volume (IV), and brain edema in cortex, piriform cortex-amygdala, as well as the striatum of the rat brain were assessed. Histopathological parameters and brain-derived neurotrophic factor (BDNF) gene expression were also evaluated. The TQ + tPBM group significantly reduced NDS, IV, and brain edema compared to the MCAO group. Increased BDNF gene expression and decreased pyknotic cells were also observed in the TQ + tPBM group. The post-treatment administration of TQ combined with tPBM (in the short term) indicated an enhanced combined effect in reducing ischemic brain damage, potentially through BDNF upregulation.
Indexed as
Identifiers
42008032What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.